TLR9 Inhibitor Pyrrolopyridines With TLR7 and TLR8 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can effectively inhibit Toll-like receptor 9 (TLR9) signaling while maintaining selectivity over TLR7 or TLR8, and these compounds should have desirable stability, bioavailability, therapeutic index, and toxicity values for druggability.
Innovation Solution
Development of a new class of substituted heteroaryl compounds that act as potent inhibitors of TLR9 signaling, with specific structures defined by Formula (I) and its variants, including stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, and prodrugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR9 inhibitors are developed to treat fibrotic diseases, then therapeutic efficacy is improved, but selectivity over TLR7 or TLR8 may be compromised
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions (R1-R6) on the core heteroaryl structure to achieve selective TLR9 binding. Different substituents at specific locations create steric and electronic properties that favor TLR9 interaction while minimizing binding to TLR7 or TLR8, thus resolving the selectivity issue.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and steric configurations to optimize TLR9 selectivity. By adjusting these parameters across the series of compounds, the invention achieves high TLR9 inhibition efficacy while maintaining discrimination against TLR7 and TLR8.
2Reliability
If compound structures are optimized for TLR9 inhibition, then therapeutic index is improved, but stability and bioavailability may be compromised
Solution Approach 1:
The patent uses intermediary structural elements such as linker groups and substituent moieties that serve as mediators between the core heteroaryl system and the pharmacological target. These intermediaries are designed to be metabolically stable while facilitating TLR9 binding, thus maintaining compound stability without sacrificing therapeutic index.
Solution Approach 2:
The patent applies composite material principles by combining the core heteroaryl structure with various stable substituent groups to create composite molecular entities. This composite approach allows optimization of the therapeutic index through structural combination while maintaining overall compound stability through the use of chemically robust building blocks.
3Object-generated harmful factors
If TLR9 signaling is inhibited to treat fibrosis, then inflammatory response is reduced, but toxicity may increase
Solution Approach 1:
The patent applies partial action by designing compounds that provide sufficient TLR9 inhibition to reduce fibrotic inflammation without excessive binding affinity that would cause off-target effects. The substituent modifications are optimized to achieve the minimum effective inhibition while minimizing toxicity, avoiding both under-dosing and over-dosing effects.
Solution Approach 2:
The patent uses structural copying and modification of known pharmacological motifs to create TLR9 inhibitors with improved safety profiles. By copying successful structural elements from related compounds and selectively modifying them, the invention maintains effective TLR9 inhibition while reducing toxicity through the removal or modification of harmful structural features.
Data Source
AI summary
The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).